Drug Profile

Cannabidiol - ANANDA Scientific

Alternative Names: A-1002-N5S; Cannabidiol - ANANDA Scientific; Liquid Structure™ Cannabidiol; Liquid Structure™ CBD; Nantheia™; Nantheia™ ATL5

Latest Information Update: 19 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ISA Scientific
Developer ANANDA Scientific; Ben Gurion University; David Geffen School of Medicine at UCLA; NYU Grossman School of Medicine
Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Phase II Opioid-related disorders; Post-traumatic stress disorders; Smoking withdrawal; Social phobia
No development reported COVID 2019 infections; Diabetes mellitus; Neuropathic pain; Psoriasis

03 Dec 2025 Ananda Scientific completes a phase-II clinical trials in Social phobia in USA (PO) (NCT05571592)
28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Neuropathic-pain(In the elderly, In adults) in USA (PO)
22 Oct 2024 Phase-II clinical trials in Smoking withdrawal in USA (PO) (NCT06218056)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com